The ex vivo chemosensitivity profile of choroidal melanoma

Anti-Cancer Drugs

Volumn 8, Issue 8, 1997, Pages 756-762

  Myatt, Nyree ^a   Cree, Ian A ^a   Kurbacher, Christian M ^b   Foss, Alex J E ^c   Hungerford, John L ^d   Plowman, P Nicholas ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

ATP; Chemosensitivity; Choroid; Eye; Growth; Melanoma

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; PACLITAXEL; TEMOZOLOMIDE; TREOSULFAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOSENSITIVITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; CHOROID NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MELANOMA; TUMOR CELLS, CULTURED;

EID: 0030780005     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199709000-00004     Document Type: Article

References (28)

1. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: a review and recommendations. Surv Ophthalmol 1992; 36: 429-38.
2. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the MD Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76: 1665-70.
3. Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res 1996; 56: 2900-3.
4. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114: 107-8.
5. Cantore M, Fiorentini G, Aitini F, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori 1994; 80: 37-9.
6. Proebstle TM, Scheibenbogen C, Sterry W, Keilholz U. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. Eur J Cancer 1996; 32A: 1530-3.
7. Logani S, Cho AS, Su LD, et al. Effects of gamma radiation on the OM431 human ocular melanoma cell line, Exp Eye Res 1995; 60: 603-5.
8. Andreotti PB, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
9. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 1996; 7: 630-5.
10. Hunter EM, Sutherland IA, Cree LA, Dewar JA, Preece PE, Andreotti PE. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19: 242-9.
11. Andreotti PE, Kurbacher CM, Lee JM, et al. Sensitivity of clinical ovarian cancer specimens to the combination of cisplatin and cytosine arabinoside: evaluation by ATP chemiluminescence assay. Proc Am Ass Cancer Res 1994; 35: 201.
12. McNamara M, dynes M, Dunne B, et al. Multidrug resistance in ocular melanoma. Br J Ophthalmol 1996; 80: 1009-12.
13. Rischin D, Webster LK, Millward MJ, et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 1996; 88: 1297-301.
14. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-91.
15. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncol Huntingt 1995; 9: 1149-58.
16. Bellamy WT. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 1996; 36: 161-83.
17. Hrycyna CA, Zhang S, Ramachandra M, Baofu N, Pastan I, Gottesman MM. Functional and molecular characterisation of the human multidrug transporter. In: Gupta S and Tsuruo T, eds. Multidrug resistance in cancer cells. Chichester: Wiley 1996: 29-38.
18. Lane DP. p53: guardian of the genome. Nature 1992; 362: 786-7.
19. Delia D, Mizutani S, Lamorte G, Goi K, Iwata S, Pierotti MA. p53 activity and chemotherapy. Nat Med 1996; 2: 724-5.
20. Petty RD, Cree IA, Sutherland LA, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biophys Biochem Research Commun 1994; 199: 264-70.
21. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 1346-60.
22. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995; 6 (suppl 6): 7-13.
23. van Moorsel CJA. Veerman G, Bergman AM, et al. Combination chemotherapy studies with gemcitabine. Semin Oncol 1997; 24 (suppl 7): S7.17-S7.23.
24. Luyten GP, Mooy CM, Post J, Jensen OA, Luider TM, de Jong PT. Metastatic uveal melanoma. A morphologic and immunohistochemical analysis. Cancer 1996; 78: 1967-71.
25. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW. TCA-100 Tumor Chemosensitivity Assay: differences in sensitivity between cultured tumor cell lines and clinical studies. J Biolumin Chemilumin 1994; 9: 373-8.
26. Kurbacher CM, Bruckner HW, Sass G, et al. In vitro ATP assay measure activity and chemomodulation of titanocenedichloride and cisplatin in human ovarian cancers. Proc Am Ass Cancer Res 1995; 36: 390.
27. Kurbacher CM, Bruckner HW, Cree IA, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 1997; in press.
28. Cree IA, Petty RD, Sutherland LA, et al. Eucidation of molecular determinants of tumour chemosensitivity by ATP-based luminescence assay. In: Campbell AC, Stanley PE, Kricka LJ, eds. Chemluminescence and bioluminescence. Ghichester: John Wiley 1994; 407-10.